Thalidomide-induced suppression of embryo fibroblast proliferation requires CYP1A1-mediated activation

Drug Metabolism and Disposition

Volumn 31, Issue 4, 2003, Pages 469-475

  Miyata, Masaaki ^a   Tamura, Etsuko ^a   Motoki, Kazuko ^a   Nagata, Kiyoshi ^a   Yamazoe, Yasushi ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; ALPHA NAPHTHOFLAVONE; CYTOCHROME P450 1A1; FURAFYLLINE; THALIDOMIDE;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL STRAIN HEPG2; DRUG EFFECT; DRUG INDUCED DISEASE; EMBRYO CULTURE; EMBRYO DEVELOPMENT; ENZYME ACTIVATION; FIBROBLAST; IMMUNOBLOTTING; IMMUNOMODULATION; LIVER MICROSOME; METABOLIC ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; TERATOGENICITY;

ANIMALS; ANTIBODIES; ANTIOXIDANTS; BLOTTING, WESTERN; CELL COUNT; CELL DIVISION; CELL SURVIVAL; CELLS, CULTURED; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EMBRYO; ENZYME INHIBITORS; FEMALE; FIBROBLASTS; IMMUNOSUPPRESSIVE AGENTS; LIVER; MICE; MICROSOMES; PLACENTA; PREGNANCY; RABBITS; THALIDOMIDE;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0037377922     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.4.469     Document Type: Article

References (37)

1. Ando Y, Fuse E, and Figg WD (2002) Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 8:1964-1973.
2. Annas A, Granberg AL, and Brittebo EB (2000) Differential response of cultured human umbilical vein and artery endothelial cells to Ah receptor agonist treatment: CYP-dependent activation of food and environmental mutagens. Toxicol Appl Pharmacol 169:94-101.
3. Arlen RR and Wells PG (1996) Inhibition of thalidomide teratogenicity by acetylsalicylic acid: evidence for prostaglandin H synthase-catalyzed bioactivation of thalidomide to a teratogenic reactive intermediate. J Pharmacol Exp Ther 277:1649-1658.
4. Bauer KS, Dixon SC, and Figg WD (1998) Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55:1827-1834.
5. Borenfreund E and Puerner JA (1985) Toxicity determined in vitro by morphological alterations and neutral red absorptions. Toxicol Lett (Shannon) 24:119-124.
6. Braun AG, Harding FA, and Weinreb SL (1986) Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450. Toxicol Appl Pharmacol 82:175-179.
7. Braun AG and Weinreb SL (1984) Teratogen metabolism: activation of thalidomide and thalidomide analogues to products that inhibit the attachment of cells to concanavalin A coated plastic surfaces. Biochem Pharmacol 33:1471-1477.
8. Calabrese L and Fleischer AB (2000) Thalidomide: current and potential applications. Am J Med 108:487-495.
9. 2+-sedimented microsomes from rat liver. Biochem Pharmacol 21:3249-3256.
10. Delahunt CS, Kiss N, Feldman E, and Oakes M (1965) Some comparative pharmacological studies in man and the monkey with thalidomide. Toxicol Appl Pharmacol 7:481.
11. Dey A, Jones JE, and Nebert DW (1999) Tissue- and cell type-specific expression of cytochrome P4501A1 and cytochrome P4501A2 mRNA in the mouse localized in situ hybridization. Biochem Pharmacol 58:525-537.
12. Eriksson T, Bjorkman S, and Hoglund P (2001) Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 57:365-376.
13. Fratta I, Sigg EB, and Maiorana K (1965) Teratogenic effects of thalidomide in rabbits, rats, hamsters and mice. Toxicol Appl Pharmacol 7:268-286.
14. Gordon GB, Spielberg SP, Blake D, and Balasubramanian V (1981) Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc Natl Acad Sci USA 78:2545-2548.
15. Hakkola J, Pasanen M, Hukkanen J, Pelkonen O, Maenpaa J, Edwards RJ, Boobis AR, and Raunio H (1996) Expression of xenobiotic-metabo[izing cytochrome P450 forms in human full-term placenta. Biochem Pharmacol 51:403-411.
16. Hakkola J, Pelkonen O, Pasanen M, and Raunio H (1998) Xenobiotic-metabolizing cytochrome P450 enzyme in the human feto-placental unit: role in intrauterine toxicity. CRC Crit Rev Toxicol 28:35-72.
17. Halpert JR, Guengerich FP, Bend JR, and Correia MA (1994) Selective inhibitors of cytochromes P450. Toxicol Appl Pharmacol 125:163-175.
18. Juchau MR, Boutelet-Bochan H, and Huang Y (1998) Cytochrome-P450-dependent biotransformation of xenobiotics in human and rodent embryonic tissues. Drug Metab Rev 30:541-568.
19. Lenz W (1962) Thalidomide and congenital abnormalities. Lancet 1:45.
20. Little SA and Mirkes PE (1992) Effect of 4-hydroperoxycyclophosphamide (4-OOH-CP) and 4-hydroperoxydichlorocyclophosphamide (4-OOH-deCICP) on the cell cycle of postimplantation rat embryos. Teratology 45:163-173.
21. McBride WG (1961) Thalidomide and congenital abnormalities. Lancet 2:1358.
22. Miyata M, Kudo G, Lee YH, Yang TJ, Gelboin HV, Fernandez-Salguero P. Kimura S, and Gonzalez FJ (1999) Targeted disruption of the microsomal epoxide hydrolase gene: microsomal epoxide hydrolase is required for the carcinogenic activity of 7,12-dimethylbenz[a]anthracene. J Biol Chem 274:23963-23968.
23. Miyata M, Motoki K, Tamura E, Furukawa M, Gonzalez FJ, and Yamazoe Y (2002a) Relative importance of maternal and embryonic microsomal epoxide hydrolase in 7,12-dimethylbenz[alanthracene-induced developmental toxicity. Biochem Pharmacol 63:1077-1084.
24. Miyata M, Tamura E, and Yamazoe Y (2002b) Development of an in vitro system detecting pro-embryotoxin. Jpn J Pharmacol 89:320-323.
25. Nicolai S, Sies H, and Stahl W (1997) Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human skin fibroblasts. Biochem Pharmacol 53:1553-1557.
26. Onat D, Stahl W, and Sies H (2001) Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human fetal skin fibroblasts (HFFF2) and rat liver epithelial cells (WB-F344) Biochem Pharmacol 62:1081-1086.
27. Parman T, Wiley MJ, and Wells PG (1999) Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 5:582-585.
28. Price DK, Ando Y, Kruger EA, Weiss M, and Figg WD (2002) 5′-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis. Ther Drug Monit 24:104-110.
29. Rey-Grobellet X, Eeckhoutte C, Sutra F, Alvinerie M, and Galtier P (1996) Major involvement of rabbit liver cytochrome P4501A in thiabendazole 5-hydroxylation. Xenobiotica 26:765-778.
30. Sauer H, Gunther J, Hescheler J, and Wartenberg M (2000) Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxy radicals. Am J Pathol 156:151-158.
31. Schuler S and Ehninger U (1995) Thalidomide: rationale for renewed use in immunological disorders. Drug Safety 12:364-369.
32. Schumacher H, Blake DA, Gurian JM, and Gillette JR (1968) A comparison of the teratogenic activity of thalidomide in rabbits and rats. J Pharmacol Exp Ther 160:189-200.
33. Stephens TD, Bunde CJ, and Fillmore BJ (2000) Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 59:1489-1499.
34. Vakharia DD, Liu N, Pause R, Fasco M, Bessette E, Zhang Q-Y, and Kaminsky LS (2001) Polycyclic aromatic hydrocarbon/metal mixtures: effect on PAH induction of CYP1a1 in human HepG2 cells. Drug Metab Dispos 29:999-1006.
35. Walmod PS, Berezin A, Gallagher HC, Gravemann U, Lepekhin EA, Belman V, Bacon CL, Nau H, Regan CM, Berezin V, et al. (2002) Automated in vitro screening of teratogens. Toxicol Appl Pharmacol 181:1-15.
36. Wells PG, Kim PM, Laposa RR, Nicol CJ, Parman T, and Winn LM (1997) Oxidative damage in chemical teratogenesis. Mutat Res 396:65-78.
37. Zwingenberger K and Wnendt S (1996) Immunomodulation by thalidomide: systemic review of the literature and unpublished observations. J Inflamm 46:177-211.